SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Agouron Pharmaceuticals (AGPH)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: David S. who wrote (3254)12/9/1997 1:30:00 AM
From: John Metcalf  Read Replies (1) of 6136
 
Sortof, Dave. Some of the causative agents of liver cancer, like pollution and the various forms of hepatitis, are increasing in frequency. It is very conceivable that a company working in the hepatic area would pay a fee and royalties for Thymitaq. It is also conceivable that JT would license it, simply because they are in Asia where liver disease is more common.

I think that Peter Johnson was in the position of a man with a beloved rusted pickup truck on the lawn, facing a disapproving wife and ongoing costs for insurance. Under those circumstances, selling the sucker gets it off your lawn, gives you a few bucks, and allows you to sleep indoors every night. (This last is a personal goal, now that Winter has come.)
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News